
Two Celltrion Denosumab Biosimilars Now Available in US
Celltrion USA, the New Jersey-headquartered United States subsidiary of South Korea-based Celltrion, announced on July 7, 2025 that two biosimilars it has developed for denosumab are now commercially available in the US (1). Biosimilars specifically …